Neurocrine Biosciences Cash Flow from Operating Activities 2010-2025 | NBIX

Neurocrine Biosciences cash flow from operating activities for the twelve months ending June 30, 2025 was $1.180B, a 20.21% increase year-over-year.

  • Neurocrine Biosciences annual cash flow from operating activities for 2024 was $0.595B, a 52.71% increase from 2023.
  • Neurocrine Biosciences annual cash flow from operating activities for 2023 was $0.39B, a 14.88% increase from 2022.
  • Neurocrine Biosciences annual cash flow from operating activities for 2022 was $0.339B, a 32.32% increase from 2021.

Neurocrine Biosciences Cash Flow from Operating Activities 2010-2025 | NBIX

  • Neurocrine Biosciences annual cash flow from operating activities for 2024 was $0.595B, a 52.71% increase from 2023.
  • Neurocrine Biosciences annual cash flow from operating activities for 2023 was $0.39B, a 14.88% increase from 2022.
  • Neurocrine Biosciences annual cash flow from operating activities for 2022 was $0.339B, a 32.32% increase from 2021.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$72.3B
Zoetis (ZTS)$68.6B
Takeda Pharmaceutical (TAK)$47.6B
Daiichi Sankyo, - (DSNKY)$46.4B
BeOne Medicines - (ONC)$32.7B
Sandoz Group AG (SDZNY)$27.7B
Summit Therapeutics (SMMT)$18.1B
Merck (MKKGY)$16.3B
Shionogi (SGIOY)$14.8B
United Therapeutics (UTHR)$13.9B
IPSEN (IPSEY)$11.6B
Orion OYJ (ORINY)$11.2B
Madrigal Pharmaceuticals (MDGL)$9.7B
Eisai (ESAIY)$9.1B
Corcept Therapeutics (CORT)$7.3B
Stevanato Group S.p.A (STVN)$7.1B
Ionis Pharmaceuticals (IONS)$6.8B
Grifols, S.A (GRFS)$6.8B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
Hypermarcas (HYPMY)$2.8B
Procaps Group, S.A (PROCF)$2.8B
NewAmsterdam Pharma (NAMS)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.2B
Dyne Therapeutics (DYN)$2B